52 in 52: CRASH-2 Trial


    52 in 52: CRASH-2 Trial

    Article Citation: CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010 Jul 3;376(9734):23-32. PMID: 20554319

    What we already know about the topic: Traumatic injuries are a major cause of death worldwide. Approximately one-third of in-hospital traumatic deaths are a result of hemorrhage. The body’s hematologic response to trauma and surgery involves fibrinolysis, or clot breakdown, which can become exaggerated and pathologic. Antifibrinolytic agents reduce blood loss in patients with normal and exaggerated fibrinolytic response to surgery. In many studies tranexamic acid (TXA) has been found to reduce bleeding in patients undergoing elective surgery. It is thought that the hematologic response in trauma and surgery are similar and TXA may reduce mortality secondary to bleeding in trauma patients.

    Why this study is important: To assess the effects of early administration of TXA on death, vaso-occlusive event and the receipt of blood in trauma patients.

    Brief overview of the study: This study was a randomized placebo controlled trial in 274 hospitals in 40 countries. Adult trauma patients with significant hemorrhage (SBP <90 or HR >110) or who were considered to be at high risk were included. Patients were randomly assigned to either receive TXA or placebo within 8 hours of injury. Patients that met a clear indication for TXA were not randomly assigned and received TXA. Primary outcome was in-hospital death within 4 weeks of injury. Intention to treat analysis found TXA significantly reduced all-cause mortality, with a relative risk reduction of 0.91. Furthermore, the risk of death secondary to bleeding was also reduced with a relative risk reduction of 0.85. There was no significant difference in vaso-occlusive events or amount of blood products between the groups.

    Limitations: The randomization process for the trial was not a true randomization. Patients who clearly met use for TXA or clearly did not met use were excluded and only those patients where it was uncertain were randomized. Only about 50% of patients in both placebo and TXA received blood products. In the US we would likely be giving a much higher percentage of patients blood products and massive transfusion. Furthermore, the patients who were included may not have been that sick: hypotensive (~32%) and tachycardic (~48%)in both groups. The most common cause of death was head injury, with only ~5% of the study population dying from hemorrhage. Finally, they were unable to assess the mechanism of TXA.

    Take home points: The study was flawed and has its fair share of critics, but followup systemic reviews and studies, including MATTERs demonstrated clear benefit to early use of tranexamic acid to hemorrhaging trauma patients.

    • Welcome! This is the website for the Mount Sinai Emergency Ultrasound Division. It serves as an information resource for residents, fellows, medical students and others seeking information about point-of-care ultrasound. There is a lot ofRead more

    • renal handling of water

      If you were on a tea & toast diet, how much water would you need to drink before you develop hyponatremia? I haven’t seen anyone work out the numbers before so here are my calculations. AndRead more

    • acute acidemia physiology

      As alluded to in the first post, don’t be fooled by a “normal” potassium in the setting of DKA because osmotic diuresis and H+/K+ exchange means that total body potassium is actually LOW. You all knowRead more

    • renal handling of potassium

      the first symptom of hyperkalemia is death Earlier post covered temporizing measures to counter hyperkalemia — namely, intracellular shift, increasing cardiac myocyte threshold potential. Give furosemide if the patient still urinates and consider dialysis, but then askRead more

    • bicarbonate revisited

      Previous post reviewed the safety of balanced crystalloids in hyper K. But what was up with serum bicarbonate decreasing with saline administration? This post introduces a new way of looking at the anion gap to possiblyRead more

    • hyperkalemia and balanced crystalloids

      Is it safe to give LR or plasmalyte to a hyperkalemic patient (these balanced crystalloids have 4-5 mEq/L K as opposed to 0 mEq/L K in normal saline)? Postponing the discussion of renal handling of potassium toRead more

    • hyperkalemia physiology

      You’ll likely encounter hyperkalemia on your next Resus / Cardiac shift, and you’ll instinctively treat it. But take a moment to review the fascinating physiology behind the “cocktail”! First, consider how K+ is buffered byRead more

    • Slow down your tachycardia (but not really)

      You’re sitting in resus bemoaning the departure of your most beloved attending when suddenly a patient wheels in without warning. The patient looks relatively stable but the triage RN tells you her heart rate wasRead more

    • Otitis externa: use the ear wick!

      Acute otitis externa (AOE) is a common complaint seen in pediatric as well as adult emergency departments. AOE is typically not accompanied by acute otitis media, although concurrent cases are possible. Also called “swimmer’s ear”Read more